Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Novo Nordisk (NYSE: NVO) and Intuitive Surgical (NASDAQ: ISRG) are both healthcare leaders, but they operate in different ...

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla ...

GreensKeeper Asset Management, an investment management company, released its third-quarter 2025 investor letter. A copy of ...

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for slowing Alzheimer’s — a disease with few treatment options.

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Ozempic is now available in India as 0.25 mg, 0.5 mg and 1 mg in 'FlexTouch Pen' - an easy-to-use, once-weekly pen device, at ...

In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of ...

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for ...

Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, talks to BT about India’s role ...

Novo Nordisk introduces Ozempic® (injectable semaglutide) in India, targeting Type 2 diabetes and weight management. Priced ...